Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules
Launched by MING-AN YU · Sep 22, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how thyroid nodules, which are lumps in the thyroid gland, affect the quality of life and emotional well-being of patients before and after treatment. The researchers want to understand how treatments like microwave ablation (a type of heat treatment) or thyroidectomy (surgery to remove part or all of the thyroid) impact patients' feelings and daily life.
To participate, individuals must be diagnosed with benign thyroid nodules or a specific type of thyroid cancer called papillary thyroid carcinoma, and they should have undergone one of the treatments mentioned. Eligible participants will be asked to complete surveys that help researchers gather information about their experiences and emotions related to their condition. The study is currently looking for participants aged 18 to 75, and it’s important for them to be able to understand and respond to the survey questions. If someone has serious health issues in areas like the liver, kidneys, or mental health, they may not be able to join this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of benign thyroid nodules or papillary thyroid carcinoma ;
- • underwent microwave ablation or thyroidectomy;
- • ability to understand and cooperate with the survey
- Exclusion Criteria:
- • serious primary diseases in the liver, kidney, hematopoietic, or endocrine systems;
- • a history of mental illness, personality disorders, cognitive impairments, or organic brain disease
About Ming An Yu
Ming-An Yu is a dedicated clinical trial sponsor committed to advancing medical research and innovation through rigorous and ethical trial management. With a focus on improving patient outcomes, Ming-An Yu oversees a diverse portfolio of clinical studies across various therapeutic areas. The organization prioritizes collaboration with healthcare professionals, regulatory bodies, and research institutions to ensure the highest standards of safety, efficacy, and compliance. By leveraging cutting-edge methodologies and data-driven approaches, Ming-An Yu aims to contribute significantly to the development of new therapies and enhance the overall landscape of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
ming'an yu, MD
Study Chair
China-JapanFriendship Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported